Hitoshi Sase

485 total citations
11 papers, 410 citations indexed

About

Hitoshi Sase is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Hitoshi Sase has authored 11 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Cancer Research. Recurrent topics in Hitoshi Sase's work include Fibroblast Growth Factor Research (4 papers), Angiogenesis and VEGF in Cancer (3 papers) and Epigenetics and DNA Methylation (2 papers). Hitoshi Sase is often cited by papers focused on Fibroblast Growth Factor Research (4 papers), Angiogenesis and VEGF in Cancer (3 papers) and Epigenetics and DNA Methylation (2 papers). Hitoshi Sase collaborates with scholars based in Japan, United Kingdom and United States. Hitoshi Sase's co-authors include Kohei Miyazono, Keiji Miyazawa, Keiko Yuki, Kiyoaki Sakata, Toshihiko Fujii, Tetsuro Watabe, Yoshito Nakanishi, Nobuya Ishii, Konstantinos J. Mavrakis and Yoshiko Nagano and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and Cancer Research.

In The Last Decade

Hitoshi Sase

11 papers receiving 396 citations

Peers

Hitoshi Sase

ONCOL

SURGE

Ryan Traynor United Kingdom

Hannah Tovell United Kingdom

Wenqian Song China

Vice Mandic Canada

Xueqiang Ding China

Teresa Corral Spain

Xun Sun China

Christine Gauglhofer Austria

Kasia Weina Germany

Cláudia Miranda Italy

Ryan Traynor United Kingdom

Hitoshi Sase

256 ×0.7

62 ×0.6

ONCOL

35 ×0.7

SURGE

33 ×0.8

38 ×1.4

Citations per year, relative to Hitoshi Sase Hitoshi Sase (= 1×) peers Ryan Traynor

Countries citing papers authored by Hitoshi Sase

Since Specialization

Citations

This map shows the geographic impact of Hitoshi Sase's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hitoshi Sase with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hitoshi Sase more than expected).

Fields of papers citing papers by Hitoshi Sase

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hitoshi Sase. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hitoshi Sase. The network helps show where Hitoshi Sase may publish in the future.

Co-authorship network of co-authors of Hitoshi Sase

This figure shows the co-authorship network connecting the top 25 collaborators of Hitoshi Sase. A scholar is included among the top collaborators of Hitoshi Sase based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hitoshi Sase. Hitoshi Sase is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Sase, Hitoshi, Yukako Tachibana, Masami Hasegawa, et al.. (2024). Abstract 1654: Anti-tumor activity of orally-available cyclic peptide LUNA18 through direct RAS inhibition in RAS-altered tumors. Cancer Research. 84(6_Supplement). 1654–1654. 3 indexed citations

Sase, Hitoshi, Yukako Tachibana, Masami Hasegawa, et al.. (2024). Abstract 1664: Combination of LUNA18, a novel RAS inhibitor, with KRAS G12C inhibitors augments anti-tumor activity via inhibition of MAPK pathway reactivation. Cancer Research. 84(6_Supplement). 1664–1664. 2 indexed citations

Tanaka, Hiroshi, Hitoshi Sase, Toshiyuki Tsukaguchi, et al.. (2018). Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer. Molecular Cancer Therapeutics. 17(12). 2519–2529. 17 indexed citations

Sase, Hitoshi, Yoshito Nakanishi, Satoshi Aida, et al.. (2018). Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2 -Amplified Gastric Cancer. Molecular Cancer Therapeutics. 17(10). 2217–2225. 17 indexed citations

Nakanishi, Yoshito, Hideaki Mizuno, Hitoshi Sase, et al.. (2015). ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor. Molecular Cancer Therapeutics. 14(12). 2831–2839. 24 indexed citations

Nakanishi, Yoshito, Toshiyuki Tsukaguchi, Toshihiko Fujii, et al.. (2014). The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor. Molecular Cancer Therapeutics. 13(11). 2547–2558. 101 indexed citations

Nakanishi, Yoshito, Toshiyuki Tsukaguchi, Toshihiko Fujii, et al.. (2014). Abstract 2729: FGFR genetic alterations as a potential predictor of the sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor with a novel chemical scaffold. Cancer Research. 74(19_Supplement). 2729–2729. 1 indexed citations

Sase, Hitoshi, et al.. (2009). VEGFR2-PLCγ1 axis is essential for endothelial specification of VEGFR2+ vascular progenitor cells. Journal of Cell Science. 122(18). 3303–3311. 38 indexed citations

Harada, Kaori, Tomoko Yamazaki, Caname Iwata, et al.. (2009). Identification of targets of Prox1 during in vitro vascular differentiation from embryonic stem cells: functional roles of HoxD8 in lymphangiogenesis. Journal of Cell Science. 122(21). 3923–3930. 28 indexed citations

10.

Watabe, Tetsuro, Hitoshi Sase, Masanori Hirashima, et al.. (2008). Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells. The Journal of Cell Biology. 181(1). 131–141. 43 indexed citations

11.

Nagano, Yoshiko, Konstantinos J. Mavrakis, Kian Leong Lee, et al.. (2007). Arkadia Induces Degradation of SnoN and c-Ski to Enhance Transforming Growth Factor-β Signaling. Journal of Biological Chemistry. 282(28). 20492–20501. 136 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact